fesoterodine fumarate

FDA Drug Profile — fesoterodine fumarate, Toviaz

Drug Details

Generic Name
fesoterodine fumarate
Brand Names
fesoterodine fumarate, Toviaz
Application Number
ANDA204946
Sponsor
Zydus Lifesciences Limited
NDC Codes
6
Dosage Forms
TABLET, FILM COATED, EXTENDED RELEASE
Routes
ORAL
Active Ingredients
FESOTERODINE FUMARATE

Indications and Usage

1 INDICATIONS AND USAGE Fesoterodine fumarate extended-release tablets are indicated for the treatment of: Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Fesoterodine fumarate extended-release tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Fesoterodine fumarate extended-release tablets are indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.